Publications by authors named "Tyler Beardslee"

Claim this Profile
L
Lorlatinib Tolerability and Association With Clinical Outcomes in Patients With Advanced - or -Rearranged NSCLC: A Brief Report.
Rohit Thummalapalli, Noura J Choudhury, Fiona Ehrich, Tyler Beardslee, Danielle Brazel

JTO Clin Res Rep· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Safety Analysis of Programmed Death 1 Pathway Inhibitors in Patients With Solid Tumor Malignancies and Preexisting Autoimmune Disease.
Jordyn Paige Higgins, Anh Viet Trinh, Marley L Watson, Tyler Beardslee, Subir Goyal

J Clin Rheumatol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Retrospective Study of Bleeding Risk with Concomitant Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor and Anticoagulation.
Akhilesh Sivakumar, Sarah E Caulfield, Chao Zhang, Subir Goyal, Mehmet A Bilen, Tyler J Beardslee

Oncologist· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of immune checkpoint blockade in self-identified Black patients with advanced non-small cell lung cancer.
Bassel Nazha, Subir Goyal, Zhengjia Chen, Anne Engelhart, Jennifer Wilkinson Carlisle, Tyler J Beardslee

Cancer· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Durvalumab and tremelimumab with or without stereotactic body radiation therapy in relapsed small cell lung cancer: a randomized phase II study.
Suchita Pakkala, Kristin Higgins, Zhengjia Chen, Gabriel Sica, Conor Steuer, Tyler Beardslee

J Immunother Cancer· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Afatinib for the treatment of mutation-positive NSCLC: A review of clinical findings.
R Donald Harvey, Val R Adams, Tyler Beardslee, Patrick Medina

J Oncol Pharm Pract· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Management of Steroid-Refractory Immune-Related Adverse Events.
Marley L Watson, Tyler Beardslee

Oncology (Williston Park)· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tacrolimus for the treatment of immune-related adverse effects refractory to systemic steroids and anti-tumor necrosis factor α therapy.
Tyler Beardslee, Amber Draper, Ragini Kudchadkar

J Oncol Pharm Pract· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alectinib and Brigatinib: New Second-Generation ALK Inhibitors for the Treatment of Non-Small Cell Lung Cancer.
Tyler Beardslee, Justin Lawson

J Adv Pract Oncol· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Precision, accuracy, and resolution-Dose selection of oral anticancer agents.
Tyler J Beardslee, R Donald Harvey

Cancer· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis